Appropriate use of angiotensin-converting enzyme inhibitors significantly reduces risks of adverse cardiovascular events and mortality in patients with cardiovascular diseases.
This Chinese expert consensus updates recommendations for the use of ACE inhibitors in the prevention and treatment of cardiovascular diseases.
Absolute Event Rate: 0% vs 0%
Angiotensin-converting enzyme inhibitors (ACEIs) have therapeutic value in various cardiovascular diseases and have protective effects on the heart, blood vessels, and kidneys; they are cornerstone drugs in the management of hypertension, heart failure, and chronic kidney disease. Despite the continual emergence of new drugs, ACEIs remain indispensable. The appropriate use of ACEIs helps reduce the risks of adverse cardiovascular events and mortality. In light of updates on the concept of interdisciplinary integration and the further accumulation of evidence from evidence-based medicine, the Chinese Society of Cardiology, the Editorial Board of the Chinese Journal of Cardiology, and the Hypertension Professional Committee of the Cross-Strait Medical and Health Exchange Association convened domestic experts in relevant fields to update the recommendations for applying ACEIs in cardiovascular diseases and to compile this consensus, with the aim of providing a reference for clinical physicians in China and improving the prevention and treatment of cardiovascular diseases.
Cai et al. (Mon,) reported a other. Appropriate use of angiotensin-converting enzyme inhibitors significantly reduces risks of adverse cardiovascular events and mortality in patients with cardiovascular diseases.